Ansell Limited (ASX:ANN): What Do FY26 Earnings and FY27 Guidance Show?

Aditi Sarkar

13 November 2026 03:25 PM AEDT

Ansell Limited (ASX:ANN): What Do FY26 Earnings and FY27 Guidance Show?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Ansell Limited (ASX:ANN) reported FY26 sales of USD 2,140.2 million.
Adjusted EBIT increased to USD 321.9 million in the financial year.
FY26 Operating Cash Flow totalled USD 270.1 million.
The company declared a final Dividend of US 41.5 cents per share.

Ansell Limited manufactures protective products for healthcare and industrial workplaces, selling gloves and other personal protective equipment internationally. On 13 November 2026, Ansell shares (ASX:ANN) traded at AUD 46.49, down 0.98% for the session. The company's August FY26 results and subsequent Annual General Meeting timetable put its segment performance, dividend payments and FY27 Earnings guidance in focus.

Healthcare and Industrial Safety Products

Ansell (ASX:ANN) operates two principal segments, Healthcare and Industrial. Healthcare supplies surgical, examination and single-use gloves as well as products for controlled environments, including cleanrooms. Industrial provides hand and body protection for mechanical and chemical hazards. Its product portfolio includes HyFlex, Ringers, MICROFLEX, TouchNTuff, GAMMEX and AlphaTec.

The company serves customers across more than 100 countries, with Demand spanning hospitals, pharmaceutical and medical-device manufacturing, laboratories, general Manufacturing and specialist industrial applications. Sales can be affected by workplace activity, purchasing patterns, product mix, tariffs and supply-chain costs.

FY26 Business Developments

In its August 2026 full-year announcement, Ansell reported that Industrial segment sales reached USD 947.3 million, an increase of 5.4% on a reported basis. The segment delivered adjusted EBIT of USD 170.6 million. Mechanical product sales increased 6.5% on the company's adjusted sales-growth measure, while Chemical increased 0.5%. The company cited products used in precision cut protection and demand in industrial markets.

Healthcare segment sales totalled USD 1,192.9 million, up 8.0% on a reported basis, and adjusted EBIT was USD 170.7 million. Adjusted sales growth included 5.6% for Exam/Single Use, 6.4% for Surgical and 10.0% for Cleanroom. The company identified demand from scientific, healthcare and specialised manufacturing customers, while also reporting some temporary stocking activity ahead of price increases.

Full-Year Financial Results and Sector Conditions

Ansell (ASX:ANN) reported FY26 Revenue of USD 2,140.2 million, up 6.8% from USD 2,003.3 million in FY25. Statutory net profit after tax reached USD 208.6 million, compared with USD 101.6 million. Adjusted EBIT increased to USD 321.9 million from USD 282.1 million, with the adjusted EBIT Margin moving to 15.0% from 14.1%. Adjusted Earnings Per Share were US 148.6 cents, versus US 126.1 cents.

Operating cash flow was USD 270.1 million, compared with USD 105.4 million in FY25. The company reported net Debt to adjusted EBITDA of 1.3 times and USD 752 million in cash and undrawn bank facilities at 30 June 2026. Its cost environment included US tariffs, increased freight and input pressures linked to the Middle East, and foreign-exchange movements. Pricing and sourcing adjustments helped offset some effects, although further changes remain possible.

Dividend, Risks and FY27 Outlook

Ansell determined a final unfranked dividend of US 41.5 cents per share, taking FY26 dividends to US 68.1 cents per share. The final dividend was paid in September 2026. The company also reported USD 118.4 million of repurchases under its existing USD 200 million on-market buyback programme during FY26.

For FY27, management guided to adjusted earnings per share of US 158–170 cents, excluding specified items and the effects of its buyback. The company also outlined USD 45–55 million of Capital spending, with an enterprise-resource-planning implementation phase among planned activities. Tariff policy, price adjustments, currency exposure, changing customer orders and execution costs remain important uncertainties. The financial calendar lists the next half-year results for February 2027.

Key Insights

Ansell (ASX:ANN) increased reported revenue, statutory profit and operating cash flow in FY26. Its operating divisions serve differing end markets, while FY27 guidance depends on the company's stated pricing, Volume and cost assumptions. Dividends, cash conversion and progress on productivity initiatives remain relevant monitoring points.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.